THERAPEUTIC RESPONSE TO PEG-INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C
Abstract
Aim To evaluate the epidemiological, clinical-biological, therapeutic and evolutive characteristics of HCV-infected patients admitted in Hospital of Infectious Disease “Sf. Parascheva” Iaşi between 2012-2017. Material and methods: 408 patients received peginterferon alfa-2a/alfa-2b plus ribavirin for 48 weeks. Clinical and laboratory data were assessed at baseline, week 4, 12, 24, 48 (end of treatment, EOT), and 24 weeks after therapy (sustained virological response, SVR). Results: The mean age of patients was 48.78±11.30 years old (range 18-75 years), most patients being female (63.5%). Ten (2.5%) patients had co-infection with hepatitis B virus (HBV), and in 14 (2.1%) IL28B polymorphism was determined. Of the 408 patients receiving PEG-IFN α and ribavirin, 35% had SVR, but 22.8% had relapses and 36.3% were non-responders. The most common side effects were leukopenia (26.2%), followed by thrombocytopenia (21.4%), anemia (17.9%) and neutropenia (12.6%). Conclusions: The SVR rate in the studied group was only 35%, this fact demonstrates the need for new antiviral therapies, especially in patients with advanced fibrosis.
References
2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. Journal of Hepatology 2014; 61: S58-S68.
3. Michael P Manns, John G. McHutchison, Stuart C Gordon, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. The Lancet 2001; 358: 958-965.
4. ***CNSCBT Analiza epidemiologica descriptiva a cazurilor de hepatita virala tip B si C, intrate in sistemul de supraveghere in anul 2012. 2014. Accessed at: http://www.cnscbt.ro/index.php/analiza-datesupraveghere/hepatita-virala-tip-b-si-c.
5. *** CNSCBT Analiza epidemiologica descriptiva a cazurilor de hepatita virala tip B si C, intrate in sistemul de supraveghere in anul 2013. 2014. Accessed at: http://www.cnscbt.ro/index.php/analiza-datesupraveghere/hepatita-virala-tip-b-si-c).
6. ***CNSCBT Analiza epidemiologica descriptiva a cazurilor de hepatita virala tip B si C, intrate in sistemul de supraveghere in anul 2015. 2014. Accessed at: http://www.cnscbt.ro/index.php/analiza-datesupraveghere/hepatita-virala-tip-b-si-c.
7. ***CNSCBT Analiza epidemiologica descriptiva a cazurilor de hepatita virala tip B si C, intrate in sistemul de supraveghere in anul 2016. 2014. Accessed at: http://www.cnscbt.ro/index.php/analiza-datesupraveghere/hepatita-virala-tip-b-si-c.
8. ***CNSCBT Analiza epidemiologica descriptiva a cazurilor de hepatita virala tip B si C, intrate in sistemul de supraveghere in anul 2017. 2014. Accessed at: http://www.cnscbt.ro/index.php/analiza-datesupraveghere/hepatita-virala-tip-b-si-c.
9. Voiculescu M, Iliescu L, Ionescu C, et al. A Cross-Sectional Epidemiological Study of HBV, HCV, HDV and HEV Prevalence in the SubCarpathian and South-Eastern Regions of Romania. J Gastroin-testin Liver Dis March 2010; 19(1): 43-48.
10. Chun-Tao Wai, Greenson JK, Fontana RJ, et al. A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C. Hepatology 2003: 38(2): 518-526.
11. Picon RV, Fendt L, Amaral K, Picon PD. Prediction of Sustained Virological Response to Peginter-feron-based Therapy for Chronic Hepatitis C: Regression Analysis of a Cohort from Rio Grande do Sul, Brazil. Euroasian Journal of Hepato-Gastroenterology 2017; 7(1): 27-33.
12. Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 sub-types: updated criteria and genotype assignment web resource. Hepatology 2014; 59(1): 318-327.
13. ***European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55(2): 245-264.
14. Pouresmaeeli M, Alavian SM, Keshvari M, et al. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2015; 15(9): e30780.
15. Iliescu G, Alam Z, White J, et al (2010). Hematological monitoring of interferon-based therapy for chronic viral hepatitis B and C. Hepatology 2010; 14: 1102-1111.
16. M P Manns, H Wedemeyer, M Cornberg. Treating viral hepatitis C: efficacy, side effects, and com-plications. Gut 2006; 55: 1350-1359.
17. Ur Rehman A, Farhad A, Mashhood A, et al. Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients. Asian Pac J Cancer Prev 2016; 17(5): 2485-2490.
18. Nomura Dresch KF, de Mattos AA, Valle Tovo C, et al. Impact of the pegylated-interferon and rib-avirin therapy on the treatment related mortality of patients with cirrhosis due hepatitis C virus. Rev. Inst. Med. Trop. Sao Paulo 2016; 58: 37.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
